Stem cell transplants show promise for macular hole repair in monkeys

Human stem cell transplants successfully repaired macular holes in a monkey model, researchers report October 3rd in the journal Stem Cell Reports. After transplantation, the macular holes were closed by continuous filling of the space with retinal tissue.

"We confirmed for the first time in a non-human primate model that embryonic stem-derived retinal organoid sheet transplantation facilitates the closure of macular holes," says senior study author Michiko Mandai of the Kobe City Eye Hospital.

Our results suggest that this method could become a practical, safe, and effective treatment option with minimal invasive risks, particularly for difficult macular hole cases."

Michiko Mandai, Kobe City Eye Hospital

Macular holes are small gaps that form in the macula-;the central part of the retina in the eye. They can cause blurred or distorted central vision, making it difficult to read, drive, or see fine details. In the past decade, advances in surgical techniques have achieved closure rates exceeding 90%, but refractory cases are still a problem. Management of recurrent macular holes after surgery is also challenging. For retinal degenerative diseases, cell-based therapy is a promising strategy for restoring visual function. Although retinal transplantation has shown good anatomic success, visual improvement is limited, and peripheral visual field defects are inevitable.

In the new study, Mandai and collaborators evaluated whether they could overcome these hurdles by transplanting human embryonic stem cell-derived retinal organoid sheets. Transplantation of the retinal tissue resulted in graft survival and maturation and the development of light-detecting retinal cells called photoreceptors, including rods and cones. Additional experiments revealed improvements in eye fixation and responses to light.

However, the researchers pointed out a few caveats, including mild transplantation rejection, which they controlled using steroid injections. "The mild rejection may have limited the functional integration of the transplanted tissue," Mandai says. "Additionally, this was a single-case result for one eye, and the model did not exactly replicate the pathology of human refractory macular holes. However, the findings suggest that the surgical technique is feasible for human macular holes."

The authors say further studies will be required to validate the advantage of the stem cell-derived retina, including the protective effect for host retinal cells. More research is also needed to understand how cell composition in the graft influences visual function. For their own part, the researchers plan to examine whether some form of synaptic communication can be established between the host and graft over a longer period of observation.

This research was supported by the Japan Agency for Medical Research and Development (AMED), the Japan Science and Technology Agency, and the Japan Society for the Promotion of Science.

Source:
Journal reference:

Iwama, Y., et al. (2024) Transplantation of human pluripotent stem cell-derived retinal sheet in a primate model of macular hole. Stem Cell Reports. doi.org/10.1016/j.stemcr.2024.09.002.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Scientists discover key protein that helps cancer cells evade CAR T cell therapy